First Center in Hong Kong Treats Patients with CyberKnife and TomoTherapy Systems

Mon Mar 11, 2013 8:33am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

Hong Kong Adventist Oncology Center Offers Full Spectrum of Disease Treatment
with State-of-the-art Technologies
SUNNYVALE, Calif.,  March 11, 2013  /PRNewswire/ -- Accuray Incorporated
(Nasdaq: ARAY), announced today that Hong Kong Adventist Oncology Center,  the
first center locally to offer both the CyberKnife Robotic Radiosurgery and
TomoTherapy Systems, hosted its official opening ceremony last week. Hong Kong
Adventist Oncology Center is a newly built cancer center that was designed to
accommodate both systems. Their TomoTherapy System was installed late last year
and their CyberKnife System was installed in  September 2006.  

"We are pleased to offer the most flexible, precise solutions for radiation
treatment planning and delivery that enable us to deliver personalized
treatments to a wide range of patients," said Dr.  Stephen Law, clinical
director of Hong Kong Adventist Oncology Center. "The CyberKnife and TomoTherapy
Systems allow our clinicians to create specialized treatments ranging from
high-precision radiosurgery for early-stage and localized disease to
image-guided, intensity-modulated radiation therapy (IG-IMRT) for more advanced
disease throughout the body."

"Our two leading-edge treatment solutions - the CyberKnife and the TomoTherapy
Systems - satisfy all the external beam radiation delivery needs of an oncology
department and give clinicians flexible, individualized treatment options to use
in their pursuit of optimal treatment outcomes." said Lionel Hadjadjeba, general
manager EIMEA and senior vice president of International Business at Accuray.
"The adoption of Accuray's versatile systems are constantly proven to provide
comprehensive treatment solutions that serve the full spectrum of radiation
oncology patients."

For more information of Hong Kong Adventist Oncology Center, please visit     

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact
are forward-looking statements and are subject to the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release relate, but are not limited, to clinical
applications, clinical results, patient outcomes, and the Company's leadership
position in radiation oncology innovation. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially from expectations, including risks detailed from time to time under
the heading "Risk Factors" in the company's report on Form 10-K filed on 
September 10, 2012, as updated in our Form 10-Qs filed on  November 8, 2012  & 
February 6, 2013, and as updated periodically by our other filings.
Forward-looking statements speak only as of the date the statements are made and
are based on information available to the Company at the time those statements
are made and/or management's good faith belief as of that time with respect to
future events. The Company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information, except to the
extent required by applicable securities laws.  Accordingly, investors should
not place undue reliance on any forward-looking statements.

SOURCE  Accuray Incorporated

Rebecca Phillips, Public Relations Manager, Accuray, +1-408-716-4773,, Kaman Ng, Manager, Marketing Communications (APAC),

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.